@article{fdi:010057143,
  title = {{L}ong-term hepatitis {B} virus ({HBV}) response to lamivudine-containing highly active antiretroviral therapy in {HIV}-{HBV} co-infected patients in {T}hailand},
  author = {{K}hamduang, {W}. and {G}audy-{G}raffin, {C}. and {N}go-{G}iang-{H}uong, {N}icole and {J}ourdain, {G}onzague and {M}oreau, {A}. and {L}uekamlung, {N}. and {H}alue, {G}. and {B}uranawanitchakorn, {Y}. and {K}unkongkapan, {S}. and {B}uranabanjasatean, {S}. and {L}allemant, {M}arc and {S}irirungsi, {W}. and {G}oudeau, {A}.},
  editor = {},
  language = {{ENG}},
  abstract = {{B}ackground: {A}pproximately 4 million of people are co-infected with {HIV} and {H}epatitis {B} virus ({HBV}). {I}n resource-limited settings, the majority of {HIV}-infected patients initiate first-line highly active antiretroviral therapy containing lamivudine (3{TC}-containing-{HAART}) and long-term virological response of {HBV} to lamivudine-containing {HAART} in co-infected patients is not well known. {M}ethodology/{P}rincipal {F}inding: {HIV}-{HBV} co-infected patients enrolled in the {PHPT} cohort ({C}linical{T}rials. gov {NCT}00433030) and initiating a 3{TC}-containing-{HAART} regimen were included. {HBV}-{DNA}, {HIV}-{RNA}, {CD}4+ {T}-cell counts and alanine transaminase were measured at baseline, 3 months, 12 months and then every 6 months up to 5 years. {K}aplan-{M}eier analysis was used to estimate the cumulative rates of patients who achieved and maintained {HBV}-{DNA} suppression. {O}f 30 co-infected patients, 19 were positive for {HB}e antigen ({HB}e{A}g). {A}t initiation of 3{TC}-containing-{HAART}, median {HBV} {DNA} and {HIV} {RNA} levels were 7.35 log10 {IU}/m{L} and 4.47 log10 copies/m{L}, respectively. {A}t 12 months, 67% of patients achieved {HBV} {DNA} suppression: 100% of {HB}e{A}g-negative patients and 47% of {HB}e{A}g-positive. {S}eventy-three percent of patients had {HIV} {RNA} below 50 copies/m{L}. {T}he cumulative rates of maintained {HBV}-{DNA} suppression among the 23 patients who achieved {HBV}-{DNA} suppression were 91%, 87%, and 80% at 1, 2, and 4 years respectively. {O}f 17 patients who maintained {HBV}-{DNA} suppression while still on 3{TC}, 4 (24%) lost {HB}s{A}g and 7 of 8 (88%) {HB}e{A}g-positive patients lost {HB}e{A}g at their last visit (median duration, 59 months). {HBV} breakthrough was observed only in {HB}e{A}g-positive patients and 6 of 7 patients presenting {HBV} breakthrough had the rt{M}204{I}/{V} mutations associated with 3{TC} resistance along with rt{L}180{M} and/or rt{V}173{L}. {C}onclusions: {A}ll {HB}e{A}g-negative patients and 63% of {HB}e{A}g-positive {HIV}-{HBV} co-infected patients achieved long-term {HBV} {DNA} suppression while on 3{TC}-containing-{HAART}. {T}his study provides information useful for the management of co-infected patients in resource-limited countries where the vast majority of co-infected patients are currently receiving 3{TC}.},
  keywords = {{THAILANDE}},
  booktitle = {},
  journal = {{P}los {O}ne},
  volume = {7},
  numero = {7},
  pages = {e42184},
  ISSN = {1932-6203},
  year = {2012},
  DOI = {10.1371/journal.pone.0042184},
  URL = {https://www.documentation.ird.fr/hor/fdi:010057143},
}